The XIII edition of the Board of Trustees of the UB and the FBG Awards is already open Blog Post

The Awards of the Board of Trustees of the University of Barcelona and the Bosch i Gimpera Foundation for the transfer of knowledge and the creation of innovative companies celebrate their thirteenth edition. These awards aim to promote the return to society of the knowledge acquired through study and research, to stress the importance of technology, knowledge, and innovation transfer projects, and to foster the creation of innovative companies and entrepreneurial culture within the UB Group. The Bosch i Gimpera Foundation is the technology transfer office of the UB since 1983 and is based in the Barcelona Science Park.

 

GalChimia renews the Crédit d’Impôt Recherche (CIR) accreditation Blog Post

GalChimia has renewed the Crédit d’Impôt Recherche (CIR) accreditation from the French Government, which certifies the company as a provider of R&D services in France. The evaluation is related to the company’s participation in the SHIKIFACTORY100 European project, aimed at the production of compounds of high added value in the chemical, food and cosmetic industries. The Galician company has doubled the surface and staff of its R&D&I center at the Barcelona Science Park, which was opened two years ago to accelerate its growth and internationalization strategy. 

 

Droplite opens seed round of 600.000€ to accelerate the manufacturing development of its smart medical diagnostics device Blog Post

Droplite, located in the Parc Cientific de Barcelona (PCB), has recently started the industrial design and manufacturing development of its smart diagnostics device, focused on point of care (POC). The company, that it was born in 2018, as a spinoff of the Institute of Photonics Sciences (ICFO), from the hand of two entrepreneurs: André Guedes (CEO) and Rafael Porcar (CTO), was recognized with the Seal of Excellence by the European Union and with the Innovative SME seal from the Ministry of Science and Innovation.

 

Genesis Biomed to invest an additional €500,000 in 2020 Blog Post

The Genesis Ventures fund, investment vehicle of several family offices managed by the consulting firm Genesis Biomed, based in the Barcelona Science Park, has announced that it will invest an additional €500,000 in the remainder of this year. The new investments will be made in several of the spin-offs of its portfolio of companies dedicated to biomedical research, in a moment of paralysis due to health and social crisis caused by the SARS-CoV-2 coronavirus.

 

EQA develops The Conformity Assessment of Good Practice for Risk Management of COVID-19 Blog Post

EQA, an assessment and certification leading company accredited by ENAC (the Spain national accreditation agency) has developed The Conformity Assessment of Good Practice for Risk Management of COVID-19, as a basis for the progressive return to normality, essential for social and economic recovery. This evaluation is available for all types of facilities and services, whether they continue with their activity or prepare to start it.

 

Researchers identify a molecular auto-control system to avoid an excessive brown adipose tissue activity Blog Post

A scientific team found, lead by Professor Francesc Villarroya, from the Faculty of Biology and the Institute of Biomedicine of the University of Barcelona (IBUB) present in PCB, found a new molecular auto-control system of lipidic metabolism, so far unknown, could help prevent the damaging effects derived from an excessive activation of the brown adipose tissue. The study is published in the journal Nature Communications.

 

The FDA licenses Chemotargets CLARITY platform Blog Post

Chemotargets –a global leader in the development of intelligence platforms and drug design prediction, headquartered in the Barcelona Science Park– has signed a license agreement for its CLARITY® platform with the Food and Drug Administration (FDA) to provide adverse event predictions and mechanistic investigation in public health risk assessments of new drug applications and existing marketed products.